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Identity 
Other names: FLJ16691 
HGNC (Hugo): PXN 
Location: 12q24.23 
Local order: Information about the local order of PXN 
can be found at ensembl.org. 
DNA/RNA 
Description 
The PXN gene is 55.314 kb and consists of 12 exons. 
This gene is a member of the Human CCDS set: 
CCDS44996, CCDS44997, CCDS44998. 
Transcription 






4 isoforms have been identified by alternative splicing. 
The 1st isoform is the normal variant and is comprised 
of 591 AA and weighs 68 kDa. The amino terminus 
region contains 5 LD-motifs, while the carboxy 
terminus contains 4 LIM-zinc binding domains. The 
protein also contains a proline rich region and several 




Found in the cytoplasm closely apposed to the plasma 
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Function 
Focal adhesion protein: This protein is a cytoskeletal 
component involved in focal actin-membrane 
attachments to the extracellular matrix. PXN can 
interact with multiple structural molecules and 
regulatory proteins to modulate adhesion, motility and 
survival of the cell by changing actin dynamics. Some 
PXN binding proteins have oncogenic equivalents, 
allowing cells to bypass normal adhesion and GF 
signaling cascades. 
Regulation: PXN activity is regulated by various 
kinases. Adhesion and GF's stimulate these kinases to 
phosphorylate LD motifs or LIM domains. Molecules 
such as Vinculin, FAK and SRC phosphorylate tyrosine 
residues of the N-terminal LD motifs. This results in 
recruitment of downstream effectors (like CRK) to 
mediate changes in cell motility or in modulation of 
gene expression via MAPK pathways. N-terminal 
serine phosphorylation has also been identified. 
Phosphorylation of serine and threonine residues of C-
terminal LIM domains results in recruitment to focal 
adhesions. Identification of the C-terminal kinases is 
currently under investigation. 
Abbreviations: CRK (CT10 sarcoma oncogene 
cellular homolog ); FAK (focal adhesion kinase); GF 
(growth factor); MAPK (mitogen activated protein 
kinase); SRC (Rous sarcoma oncogene cellular 
homolog). 
Homology 
Member of the paxillin family, containing the 4 LIM-





Several single nucleotide polymorphisms have been 
identified. Point mutations between the LD1 and LD2 
motifs have been associated with lung cancer, the 
A127T mutation being the most frequent mutation 
(Jagadeeswaran, et al., 2008). 
Implicated in 
Head and neck cancers 
Note 
PXN overexpression has been reported in various head
and neck cancers (Li et al., 2008; Dai et al., 2010; Shi 
et al., 2010). Metallopanstimulin-1 expression has been 
associated with reduced PXN levels and tumor growth 
rate (Dai et al., 2010). 
Lung cancer 
Note 
A significant correlation was found between the  
presence of the A127T mutation between the LD1 and 
LD2 regions of PXN with non small cell lung cancer 
(Jagadeeswaran et al., 2008). A possible mechanism is 
that mutations between the LD1 and 2 regions confer 
resistance to calpain mediated proteolysis of PXN 
(Cortesio et al., 2011). However, two later studies did 
not find this mutation to exist in lung cancer or any 
other solid tumor (Pallier et al., 2009; Kim et al., 2011).  
Overexpression of PXN in non small cell lung cancer 
has been reported with less controversy (Jagadeeswaran 
et al., 2008; Zhao et al., 2010; Mackinnon et al., 2011). 
The overexpression could possibly be due to 
rearrangements on chromosome 12 (Wu et al., 2010). 
Breast cancer 
Note 
Metastatic potential was found to be directly relatd o 
PXN levels (Cai et al., 2010). The relationship between 
PXN and Her-2 expression is controversial. A study in 
2007 found a direct relationship between the 2 markers 
(Short et al., 2007) while a 2011 study found no such 
link (Panousis et al., 2011). 
Prostate cancer 
Note 
PXN up regulation was found to promote adhesion and 
motility of prostate cancer cells (Bokobza et al., 2010). 
To be noted 
Note 
The link between PXN mutations and increased growth 
rate and invasion of cancer cells is controversial. On 
the contrary, amplification and/or overexpression of 
PXN has been consistently reported in the literature. 
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